Exciting Partnership Redefines Cell and Gene Therapy Landscape: Nucleus Biologics and Core Biogenesis Join Forces
In a groundbreaking move, Nucleus Biologics, known as The Cell Performance Company™, proudly announces a transformative partnership with Core Biogenesis to revolutionize the cell and gene therapy market. This collaboration positions Nucleus Biologics as the GMP manufacturer and key distributor of Core Biogenesis’ cutting-edge recombinant proteins. Notably, Nucleus Biologics and Stoic Bio will integrate these innovative proteins into their Krakatoa™ pod-based media manufacturing systems.
Central to Nucleus Biologics’ disruptive approach is a commitment to transparency, empowering therapy developers through cloud-based tools and leveraging scientifically proven studies on the efficacy of individual media components in cell and gene therapies. The collaboration also emphasizes Core Biogenesis’ environmentally friendly protein portfolio, resulting in 65% less CO2 emissions in Krakatoa systems compared to conventional media.
Alexandre Reeber, CEO of Core Biogenesis, and David Sheehan, CEO of Nucleus Biologics and Stoic Bio, express excitement about the partnership, highlighting the shared vision of shifting the cost structure for recombinant proteins and providing sustainable alternatives. This collaboration, set to introduce a unique service offering, symbolizes a paradigm shift in the development and manufacturing of cell and gene therapies, showcasing the convergence of technology and sustainability to create better therapies sustainably and cost-effectively.
About Nucleus Biologics
Nucleus Biologics, The Cell Performance Company, is the leading provider of custom cell-growth media, tools, and technologies for cell and gene therapy. Their mission is to speed the time from scientific discovery to cure by delivering innovative, transparent, and cGMP products and services with the goal of disrupting the market and eliminating antiquated practices and products. Ultimately, Nucleus Biologics strives to create a new paradigm that serves both scientists and clinicians while reducing the environmental footprint of cell culture.
About Core Biogenesis
Core Biogenesis is building the future of recombinant protein manufacturing with its ultra-scalable and sustainable plant-based bioproduction platform. By developing the building blocks to produce any recombinant protein with its platform in a repeatable, scalable, and sustainable way, Core Biogenesis enables the delivery of cost-effective sustainable recombinant proteins for biopharmaceutical and research applications. Core Biogenesis’ first products are growth factors, cytokines, and other recombinant proteins used in Cell Culture and Bioprocessing.